ArticleClinical rheumatology2026
Disparities in clinical characteristics and health-related quality of life among young, young-onset elderly and elderly-onset rheumatoid arthritis patients: A large-scale national survey.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis study aimed to compare the clinical characteristics and health-related quality of life (HRQoL) among patients with elderly-onset rheumatoid arthritis (EORA), young-onset elderly rheumatoid arthritis (YOERA), and young rheumatoid arthritis (YRA).
methodsA multicenter cross-sectional study was conducted across 331 clinical centers in China, enrolling 15835 patients with rheumatoid arthritis (RA). Participants were categorized into YRA (onset and current age ≤ 60 years), YOERA (onset age ≤ 60 years and current age > 60 years), and EORA (onset age > 60 years). Demographic and clinical variables, disease activity, joint counts, comorbidities, follow-up regularity, medication adherence, and HRQoL (EQ-5D Utility Index and EQ-VAS) were compared among groups. TriMatch propensity score matching was used to minimize confounding. Multivariable logistic regression identified factors associated with poor HRQoL in elderly RA patients.
resultsThe proportion of females was lower in the YRA group than in the EORA group (p < 0.001). Both EORA and YOERA groups exhibited higher disease activity and comorbidity rates than YRA (p < 0.001). YOERA showed longer disease duration, less regular follow-up, and poorer medication adherence (p < 0.001). The EORA and YOERA groups both exhibited significantly higher use rates of glucocorticoids and leflunomide (p < 0.001 or p = 0.01); in contrast, the EORA group showed lower prescription rates for methotrexate, hydroxychloroquine, sulfasalazine, TNF inhibitors, and JAK inhibitors compared to the other two groups (p < 0.05). After matching, EORA and YOERA had significantly lower HRQoL scores than YRA (p < 0.001), with no difference between EORA and YOERA. Among elderly patients, older age (OR = 0.97, 95%CI 0.96 ~ 0.98), disease activity (OR = 0.36, 95%CI 0.32 ~ 0.39), and multimorbidity (OR = 0.63, 95%CI 0.55 ~ 0.72) were significant related factors for poor HRQoL, whereas regular follow-up (OR = 2.32, 95%CI 1.91 ~ 2.77) and good medication adherence (OR = 1.33, 95%CI 1.14 ~ 1.56) was protective.
conclusionsEORA and YOERA patients experience poorer HRQoL than YRA, largely due to higher disease activity, multiple comorbidities, and irregular follow-up. Key Points • RA patients with different ages of onset show distinct clinical characteristics. • Both elderly-onset and young-onset elderly RA patients exhibited poorer HRQoL than young RA patients. • Disease activity, multiple comorbidities, and irregular follow-up were significantly associated with poor HRQoL in elderly RA patients.
Indexed as
Identifiers
41428031What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.